Overall Status

Completed (3)

Recruiting (1)

Unknown status (1)

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Alexander Kolevzon (1)

Rambam Health Care Campus (1)

Simons Searchlight (1)

University of California, Los Angeles (1)

University of California, San Francisco (1)

Collaborator

Columbia University (2)

Beth Israel Deaconess Medical Center (1)

Duke University (1)

Geisinger Clinic (1)

Massachusetts General Hospital (1)

Nathan Kline Institute for Psychiatric Research (1)

Simons Foundation (1)

University of Maryland (1)

Washington University School of Medicine (1)

Intervention

al-108 (1)

davunetide (al-108, nap) (1)

ketamine (1)

placebo (1)

placebo nasal spray (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (5)

Study Type

Interventional (3)

Observational (2)

ADNP

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

ADNP Syndrome Trial in New York (Ketamine)

Completed

ADNP Syndrome

Ketamine

New York, New York

Icahn School of Medicine at Mount Sinai

Jun 28, 2021

People Who Have Genetic Changes and Features of Autism: Simons

Recruiting

16P11.2 Deletion Syndrome
+184 more

New York, New York
+1 more

Jan 6, 2023

Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome

Completed

Predicted Tauopathies, Including
+4 more

davunetide (AL-108, NAP)
Placebo nasal spray

San Francisco, California

University of California, San Francisco (UCSF)

Apr 3, 2019

Schizophrenia Trial in United States (AL-108, Placebo)

Completed

Has Results

Schizophrenia

AL-108
Placebo

Los Angeles, California
+7 more

Jan 30, 2017

Alzheimer's Disease and Frontotemporal Dementia: Preventative

Unknown status

Alzheimer's Disease

Haifa, Israel

Rambam Hospital

Jul 26, 2011